Allergan ready to take a loss by selling Teva shares

pharmafile | November 2, 2017 | News story | Sales and Marketing Allergan, Mylan, Teva, biotech, drugs, pharma, pharmaceutical 

Allergan sold its generic business to Teva back in August 2016 for a sum of $33 billion and 100 million shares of the latter company – it is now widely considered a deal of almost perfect timing, with the generics market crashing in value not long after the deal was completed.

However, the price of Teva’s shares have dipped considerably since then, falling from a value of $5.3 billion commensurately with the former company’s share price capitulation over the last year (down from a value of 16,470 to 4,986 shekels).

Allergan announced, as part of its Q3 report, that it would look to offload its shares in the company; in terms of timeframe, the sale of shares would likely take place over the next two quarters until completion.

The decision comes as it was forced to announce another impairment of Teva securities to the value of $1.3 billion, contributing to an overall operating loss of $4.03 billion for the quarter.

In brighter news for the company, it revealed that net revenues were up by 11.4% in comparison to the same quarter last year – driven by higher sales of Restasis and the added sales of several newly acquired companies, including Coolsculpting.

“Allergan’s results and outlook demonstrate the foundational strength of our Company. Our 11 percent revenue growth in the third quarter was powered by significant year-over-year gains from many of our top products, including Botox, Juvederm Collection, Linzess, Alloderm and CoolSculpting. We tightly managed our SG&A expenses, and our R&D team is making important progress across key programs, especially in advancing our six ‘stars’, including the NDA acceptance of Esmya for uterine fibroids,” said Brent Saunders, Chairman and CEO of Allergan.

Restasis patent losses were a major topic of conversation during earnings calls with Saunders. He announced that the company would be stepping back from making any further acquisitions whilst the company deals with the fallout from its controversial deal to divest rights to a North American Tribe to avoid inter partes review challenges to its patents, as well as dealing with legal action to protect the product from rivals, such as Teva and Mylan.

The mention of splitting the company up arose again but Saunders suggested that the timing would not be right, as by the time this process could be completed, patent losses would have already occurred on Restasis.

This will not such calls from investors, who believe that the share value of the company is significantly undervalued and could be boosted by splitting up the business.

Ben Hargreaves

Related Content


Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content